Research programme: Therapeutics - Evopoint Biosciences
Alternative Names: XNW***; XNW-seriesLatest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Sinovent
- Developer Evopoint Biosciences
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Unspecified in China
- 20 Oct 2020 Preclinical trials in Unspecified in China (unspecified route) before October 2020 (Sinovent pipeline, October 2020)